RIGL earnings date and last-quarter result: last quarter miss, P/E 1.88. Updated 2026-07-23.
Rigel Pharmaceuticals (RIGL) Research Hub
Rigel Pharmaceuticals (RIGL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 49.91 USD (+3.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 1.88, market cap 0.71B. This hub links to the full technical, earnings and options research available for RIGL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 49.91 USD (+3.70%) |
| 52-week range | 32.71 USD – 50.49 USD |
| Trend regime | Range |
| 14-day RSI | 65.3 (Bullish) |
| Trailing P/E | 1.88 |
| Market cap | 0.71B |
| Dividend yield | 0.00% |
Available research for RIGL
Covered Call on RIGL: how it works, illustrative setup around the real 49.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on RIGL: how it works, illustrative setup around the real 49.91 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on RIGL: how it works, illustrative setup around the real 49.91 USD price, max profit/loss, breakeven and when to use it. Educational.
RIGL technical analysis: range, last 49.91 USD, RSI 65.3, 52w range 32.71 USD–50.49 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is RIGL in?
Rigel Pharmaceuticals (RIGL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is RIGL in an uptrend or downtrend?
As of 2026-10-26, RIGL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is RIGL's trailing P/E ratio?
RIGL's trailing P/E is 1.88, with a market cap of 0.71B. See the earnings research page for full valuation detail.